Du är här


Minerva Neurosciences, Inc.: Minerva Neurosciences Announces Completion of Patient Enrollment in Phase IIa Trial of MIN-117 in Major Depressive Disorder

WALTHAM, Mass., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc.
(NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the
development of therapies to treat central nervous system (CNS) disorders,
today announced the completion of patient enrollment in a randomized,
placebo-controlled double-blind European Phase IIa clinical trial of MIN-117
in major depressive disorder (MDD).

The primary objective of this trial is to evaluate the efficacy of MIN-117
compared to placebo in reducing the symptoms of a major depressive episode as
measured by the change from baseline in the Montgomery-Asberg Depression
Rating Scale (MADRS) total score over six weeks of treatment. Additional
objectives include the assessment of onset to response, severity of illness,
sexual function, executive function, working memory, and safety and
tolerability. Eighty-four patients have been enrolled across the four
treatment arms of this study (0.5 and 2.5 mg daily of MIN-117, placebo, and
20 mg daily of paroxetine). Top line results are expected in the second
quarter of 2016.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company
focused on the development and commercialization of a portfolio of products
to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in
Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), in Phase IIa
and Phase Ib development for insomnia and the adjunctive treatment of MDD,
respectively; MIN-117, in Phase IIa development for MDD; and MIN-301, in
pre-clinical development for Parkinson's disease. Minerva's common stock is
listed on the NASDAQ Global Market under the symbol "NERV." For more
information, please visit www.minervaneurosciences.com.

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995, as amended. Forward-looking statements are statements that are not
historical facts, reflect management's expectations as of the date of this
press release, and involve certain risks and uncertainties. Forward-looking
statements include statements herein with respect to the timing and results
of future clinical milestones with MIN-117; the clinical and therapeutic
potential of MIN-117; and our ability to successfully develop and
commercialize MIN-117. These forward-looking statements are based on our
current expectations and may differ materially from actual results due to a
variety of factors including, without limitation, whether MIN-117 will
advance further in the clinical trials process and whether and when, if at
all, it will receive final approval from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies and for which
indications; whether MIN-117 will be successfully marketed if approved;
whether our therapeutic product discovery and development efforts with
MIN-117 will be successful; our ability to achieve the results contemplated
by our co-development agreements; management's ability to successfully
achieve its goals; our ability to raise additional capital to fund our
operations on terms acceptable to us; and general economic conditions. These
and other potential risks and uncertainties that could cause actual results
to differ from the results predicted are more fully detailed under the
caption "Risk Factors" in our filings with the Securities and Exchange
Commission, including our Quarterly Report on Form 10-Q for the quarter ended
September 30, 2015, filed with the Securities and Exchange Commission on
November 5, 2015. Copies of reports filed with the SEC are posted on our
website at
www.minervaneurosciences.com. The forward-looking statements in this press
release are based on
information available to us as of the date hereof, and we disclaim any
obligation to update any forward-looking statements, except as required by


William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.